CLARITY-101: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies in CALR-mutant Myeloproliferative Neoplasms (clinicaltrials.gov) - Oct 1, 2026 - P1 | N=250 | Recruiting | Sponsor: Damora Therapeutics
CALR • New P1 trial • Myeloproliferative Neoplasm • Oncology • CALR
|